Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Moderna, Merck Report Positive Results From Cancer-Vaccine Study

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
WSKG

The near death -- and last-minute reprieve -- of a trial for an HIV vaccine

A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...

Lateral Flow Assay Market Projected to Reach US$ 17.66 Billion by 2035, Reflecting Ongoing Innovation and IP Activity | Astute Analytica

Future expansion hinges on integrating digital connectivity with lab-quality sensitivity to solidify decentralized care.